Gastric cancer treated with pressurized intraperitoneal aerosol chemotherapy: revising an option for peritoneal carcinomatosis

Macedo, Filipa; Ladeira, Kátia; Longatto‐Filho, Adhemar; Martins, Sandra F.

doi:10.20517/2394-4722.2017.72

Cited by 3 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Сроки наблюдения за больными составили от 10 до 37,9 мес. В основной группе медиана ВБП составила 15,8 мес, с интерквартильным размахом (13,(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)1), в группе контроля -11,2 (10,(3)(4)(5)(6)(7)(8)(9)(10)(11)6) мес (р<0,001; χ 2 =47,662). Медиана ОВ в основной группе составила 18,7 мес, с интерквартильным размахом (15,0-24,3), в контрольной группе -12,7 (11.3-13.1) мес (р<0,001; χ 2 =50,731).…”

Section: результатыunclassified

“…Большинство авторов считают нецелесообразным циторедукцию при РЖ с подтвержденной диссеминацией по брюшине, рекомендуя паллиативную химиотерапию [11][12][13]. В рутинной клинической практике оперативное лечение при РЖ с ПК выполняется по жизненным показаниям (перфорация, угроза фатального кровотечения из распадающейся опухоли, декомпенсированный стеноз) [14].…”

Section: Introductionunclassified

See 1 more Smart Citation

Combined modality treatment of patients with stage IV gastric cancer with peritoneal carcinomatosis

et al. 2023

View full text Add to dashboard Cite

Peritoneal carcinomatosis is associated with poor prognosis in gastric cancer patients. Stage IV gastric cancer (GC) is diagnosed in 39.8 % of patients; local metastases without evidence of distant metastases occur only in 18–20 % of stage IV gastric cancer patients.The purpose of the study was to estimate the efficacy of personalized chemotherapy in the combined modality treatment of patients with stage IV GC with peritoneal carcinomatosis.Material and Methods. Cytoreductive surgery was performed in 70 patients with GC with peritoneal dissemination. The control group patients (n=35) received postoperative chemotherapy with the FOLFOX regimen. The study group patients (n=35) received personalized systemic and intraperitoneal chemotherapy based on the expression of chemosensitivity and resistance genes.Results. The median survival time (18.7 months) in the study group patients was higher than that in the control group and in studies described in the world literature (CRS + HIPEC). Personalized chemotherapy improved median progressionfree survival (PFS) by 4.6 months (29.1 %) and median overall survival (OS) by 6 months (32 %) compared to FOLFOX regimen chemotherapy. In the study group, the 1-, 2and 3-year survival rates were observed in 35 (100 %), 9 (27 %) and 1 (3 %) patients, respectively.Conclusion. Personalized chemotherapy in the combined modality treatment can improve long-term treatment outcomes (longer median PFS and OS) in GC patients with peritoneal dissemination.

show abstract

Section: результатыunclassified

Section: Introductionunclassified

Combined modality treatment of patients with stage IV gastric cancer with peritoneal carcinomatosis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The use of systemic and intraperitoneal chemotherapy in neoadjuvant mode (neoadjuvant intra peritoneal and systemic chemotherapy (NIPS)) is extremely ineffective, and only in isolated cases, it leads to the disappearance of peritoneal disseminates and positive cytology of abdominal washings (R0), in patients with initially unresectable disseminated GC. This approach is called “conversion surgery” [ 14 ]. Cytoreductive surgery (CRS) (removal of the primary tumor, and macroscopically visible metastatic foci) without chemotherapy in the postoperative period does not lead to a significant increase in the overall survival (OS) of patients [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Gene Expression Profile-Guided Personalized Intraperitoneal Chemotherapy for Gastric Cancer Peritoneal Carcinomatosis

Markovich,

Tuzikov,

Rodionov

et al. 2024

World J Oncol

View full text Add to dashboard Cite

Background Peritoneal carcinomatosis (PC) is one of the most unfavorable sites of metastasis for malignant tumors of various localizations, especially gastric cancer (GC). According to the literature, synchronous PC in GC is common in 15-52% of patients. The purpose of this study was to examine the long-term results using personalized systemic and intraperitoneal chemotherapy as part of the combined treatment of stomach cancer presenting with synchronous PC. Methods Cytoreductive surgical treatment was performed for 70 patients at the first stage. The control group (n = 35) received standard postoperative chemotherapy according to the FOLFOX scheme. Personalized postoperative systemic and intraperitoneal chemotherapy was administered in the basic group (n = 35), based on the expression levels of the eight genes in the primary tumor, lymph node, and peritoneal metastases. Results The median progression-free survival was 14.9 months in the basic group, and in the control group it was 11.2 months (P < 0.001). The median life expectancy in the basic group was 16.8 (13.7 - 18.8) months, in the control group it was 12.5 (11.3 - 13.1) months (P < 0.001). Conclusions Developing algorithms of personalized systemic and intraperitoneal chemotherapy in patients with GC with synchronous carcinomatosis, based on the analysis of molecular genetic characteristics of the tumor and metastases, allows to improve the long-term results of combined treatment.

show abstract

“…Sugarbaker [11] summarized the role and efficacy of neoadjuvant systemic chemotherapy, neoadjuvant intraperitoneal and systemic chemotherapy, cytoreductive surgery, and perioperative chemotherapy including hyperthermic intraperitoneal chemotherapy and/or early postoperative intraperitoneal chemotherapy as prevention or treatment for PC. Macedo et al [12] introduced pressurized intraperitoneal aerosol chemotherapy as a treatment option for PC.…”

mentioning

confidence: 99%

Introduction to the special issue on reviews of gastric cancer metastasis and treatment

Watanabe¹

2018

JCMT

View full text Add to dashboard Cite

Gastric cancer treated with pressurized intraperitoneal aerosol chemotherapy: revising an option for peritoneal carcinomatosis

Cited by 3 publications

References 11 publications

Combined modality treatment of patients with stage IV gastric cancer with peritoneal carcinomatosis

Combined modality treatment of patients with stage IV gastric cancer with peritoneal carcinomatosis

Gene Expression Profile-Guided Personalized Intraperitoneal Chemotherapy for Gastric Cancer Peritoneal Carcinomatosis

Introduction to the special issue on reviews of gastric cancer metastasis and treatment

Contact Info

Product

Resources

About